Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in Chronic Spontaneous Urticaria
NCT06795373Phase 2Withdrawn
- Start
- Dec 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ritlecitinib tosilate in chronic spontaneous urticaria (CSU). Primary endpoint: Urticaria Activity Score over 7 days at 12 weeks. Planned start Dec 2025; status: withdrawn.
02
Drugs
ritlecitinib tosilate
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06795373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06795373.